Detalhe da pesquisa
1.
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 200-208, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33972742
2.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 190-199, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824476
3.
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(3): 465, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079081
4.
Understanding the Specific Implications of Amino Acids in the Antibody Development.
Protein J
; 43(3): 405-424, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724751
5.
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Cancer Treat Rev
; 87: 102022, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32334240
6.
Signaling by small GTPases in the immune system.
Immunol Rev
; 218: 92-101, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17624946